Bowens-Riggins v. Pfizer, Inc | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for Bowens-Riggins v. Pfizer, Inc

Sort by

Viewing results 1‒17 of 17

Covid-19 vaccines
Pfizer and Moderna forecast to almost double vaccine sales in 2022
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
October 18, 2021
Covid-19 vaccines
Africa will pay more for Russian Covid vaccine than ‘western’ jabs
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
February 25, 2021
FT Live
Investing in America
Foreign companies as drivers of US growth, resilience and competitiveness
Tuesday, 10 DecemberHybrid Conference
FT AlphavilleCoronavirus
The ESG case for the Oxford/AstraZeneca vaccine
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
December 23, 2020
Coronavirus treatment
EU fast-tracks process for Pfizer and BioNTech’s Covid-19 vaccine
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
October 6, 2020
Technology sector
FT-Bowen Craggs Index 2014: Overview
...The writer is senior consultant at Bowen Craggs & Co. For the full ranking by different metrics, visit www.bowencraggs.com/FT-Bowen-Craggs-Index...
October 12, 2014
LexMergers & Acquisitions
Letter from Lex: let’s make a deal
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
May 16, 2014
FT Live
Due Diligence Live
Where leaders in investment and finance meet
Tuesday, 8 OctoberLondon, UK
beyondbricsNeil Munshi
Ranbaxy’s high blood pressure day
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
November 30, 2011
European banks
BRIC companies and the web
...David Bowen is senior consultant for Bowen Craggs & Co, a web effectiveness consultancy (www.bowencraggs.com). dbowen@bowencraggs.com...
October 24, 2011
US equities
Altria gains on court snub to anti-tobacco
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
June 28, 2010
FT AlphavilleEquities
CDS report: Spreads widen as investors await earnings season
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
July 6, 2009
News in-depthUK economy
Raised spirits
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
September 11, 2009
World
Corporate websites: The FT-Bowen Craggs Corporate Website Index
...David Bowen is website effectiveness consultant for Bowen Craggs & Co (dbowen@bowencraggs.com)...
April 2, 2008
European companies
InBev seeks to replace Anheuser board
...former Dun & Bradstreet chief executive and chairman Allan Loren; former Lockheed general counsel William Vinson; former ArvinMeritor chief executive Larry Yost; Houlihan Lokey managing director Marjorie Bowen...
July 7, 2008
Mergers & Acquisitions
Signatories: ICC letter on the Doha Round to the editor of the Financial Times
...Kindler, Chairman and CEO, Pfizer Inc., USA Klaus Kleinfeld, President and CEO, Siemens AG, Germany Mustafa V....
February 28, 2007
IPOs
Interview transcript
...So our position is different than what J&J’s doing or what Novartis is doing, what Pfizer is doing…and what some other companies are doing....
March 26, 2006
FT Live
Managing Operational Risk in M&A Transactions
Examining the value of business licensing and property tax in the deal cycle
Thursday, 20 JuneDigital Conference
Work & Careers
The big defence challenge
...He was born in 1954, the year, as he points out, of the famous Brown v Board of Education case which paved the way for US desegregation....
April 20, 2005
Mergers & Acquisitions
Merck's fall from grace
...Even after Vioxx's withdrawal Mr Gilmartin has the unequivocal support of the board, says William Bowen, a Merck director. "Ask me a hard question," he says....
November 17, 2004

Previous pagePage 1 of 1Next page